search
Back to results

Trial Comparing Treatment Strategies in Triangular Fibrocartilage Complex Ruptures (REINFORCER)

Primary Purpose

Triangular Fibrocartilage Complex Injury

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Arthroscopic Debridement
Placebo surgery
Arthroscopic or Open Repair
Physiotherapy
Sponsored by
Tampere University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Triangular Fibrocartilage Complex Injury focused on measuring Arthroscopy, Surgery, Triangular Fibrocartilage, Randomized Controlled Trial, Placebo, Repair, Wrist

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ulnar sided wrist pain
  • age more than 18 years
  • suspicion of TFCC tear in clinical examination (MRI optional)
  • ability to fill the Danish, Finnish, Norwegian or Swedish versions of questionnaires
  • symptom duration more than 3 months, and unsuccessful conservative treatment
  • central, radial or ulnar tear explaining the pain in arthroscopy

Exclusion Criteria:

  • unstable DRUJ which will be defined as "sign of complete instability in clinical examination"
  • distal TFCC tear in arthroscopy
  • ulnocarpal or DRUJ arthrosis
  • ulnar variance ≥ +2 mm in x-rays
  • age above 65 years
  • rheumatoid arthritis or other inflammatory disease effecting radio- or ulnocarpal or DRUJ
  • Lunotriquetral instability diagnosed in arthroscopy
  • ECU instability
  • massive tear and degenerated edges or frayed tear which fails suture

Sites / Locations

  • Copenhagen University Hospital Gentofte
  • Central Finland Central HospitalRecruiting
  • Tampere University HospitalRecruiting
  • Oulu University Hospital
  • Kuopio University HospitalRecruiting
  • Helsinki University Hospital
  • Turku University Hospital
  • Østfold Hospital Trust
  • Karolinska University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Active Comparator

Arm Label

Central or Radial Tear: Arthroscopic debridement

Central or Radial Tear: Sham surgery

Ulnar Tear: Arthroscopic or open repair

Ulnar Tear: Physiotherapy

Arm Description

Arthroscopic debridement

Diagnostic arthroscopy only (placebo surgery).

Arthroscopic or open repair

Diagnostic arthroscopy and physiotherapy

Outcomes

Primary Outcome Measures

Patient-Rated Wrist Evaluation (PRWE)
PRWE questionnaire is a validated wrist specific questionnaire consisting of 15-item questionnaire about pain and disability in daily living. PRWE gives a value between 0 (best) and 100 (worst). It is specific wrist instrument with good reliability, validity and responsiveness. In this trial we use minimal important difference (MID) value of 8. It is evaluated pre- and postoperatively.

Secondary Outcome Measures

EQ-5D-3L
Health-related quality of life is measured pre- and postoperatively by EQ-5D-3L questionnaire. It is a generic instrument for assessing quality of life comprising five dimensions and VAS for health level. It is validated and widely used in healthcare research.
Adverse and serious adverse events
We will record all adverse events: tendon, ligament, nerve or arterial injury; fracture, CRPS, infection, chondral lesion and hematoma or any other condition, which can be attributed to the intervention. We will consider events leading to hospitalisation or death as serious adverse events and these will be recorded.
Patient rated global improvement
Global improvement is evaluated pre- and postoperatively by the question: "How would you rate the function and pain of your wrist compared to the situation before the treatment?" The options are in 7-step Likert scale from (-3) "Much worse" to (+3) "Much better". We will dichotomize the response between 0 (not better or worse) +1 (slightly better).
Pain (VAS) in activity
VAS in use is assessed pre- and postoperatively by VAS scale. The measurement of wrist pain in the affected hand is measured using a 100-mm horizontal line. Pain score is measured between 0 (mm, no pain) and 100 (mm, worst possible) pain. Higher score means worse outcome.
Grip strength
Grip strength is measured pre- and postoperatively with Jamar dynamometer using the handle in 2-position. Elbow is in 90° flexion and attached to chest. The result is reported in kilograms.
Success of blinding with the patient and the outcome assessor
At the two-year control it is asked from the patient and the outcome assessor which group they thought to belong treatment or placebo in central or radial tear randomization cohort. The success of blinding will be reported in per cents.

Full Information

First Posted
September 29, 2020
Last Updated
August 25, 2021
Sponsor
Tampere University Hospital
Collaborators
Central Finland Central Hospital, Helsinki University Central Hospital, Turku University Hospital, Kuopio University Hospital, Oulu University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04576169
Brief Title
Trial Comparing Treatment Strategies in Triangular Fibrocartilage Complex Ruptures
Acronym
REINFORCER
Official Title
tREatment of Triangular FibrOcaRtilage ComplEx Ruptures (REINFORCER): Protocol for Trial Comparing Debridement Versus Diagnostic Arthroscopy in Central or Radial Tears and Physiotherapy Versus Repair in Ulnar Tears
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
October 27, 2020 (Actual)
Primary Completion Date
March 31, 2027 (Anticipated)
Study Completion Date
March 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tampere University Hospital
Collaborators
Central Finland Central Hospital, Helsinki University Central Hospital, Turku University Hospital, Kuopio University Hospital, Oulu University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Trial is a prospective, randomized, controlled, outcome assessor and participant (in other randomization cohort of the trial) blinded, two randomization cohorts, which each has two parallel 1:1 arms, a multinational and -centre trial comparing the efficacy of 1) debridement with placebo surgery and 2) repair with physiotherapy. The primary objective is to compare efficacy of surgery, depending on the type of injury, with either placebo surgery or physiotherapy in 1-year follow-up in two randomization cohorts.
Detailed Description
Triangular fibrocartilage complex (TFCC) injuries are often considered the cause of ulnar wrist pain. TFCC lesions can be traumatic or degenerative according to classification suggested by Palmer and Atzei. Primary treatment is conservative, but if symptoms persist, operative treatment is an option. Depending on the morphology of the tear, the treatment can be either debridement or repair. Trialists have observed improvement of symptoms after TFCC repair but all these trials are observational cohorts without proper controls. Efficacy of surgery has not been studied in randomized controlled trial (RCT) setting. The investigators planned a prospective, randomized, controlled, outcome assessor and participant (in other randomization cohort of the trial) blinded, two randomization cohorts, which each has two parallel 1:1 arms, a multinational and -centre trial comparing the efficacy of 1) debridement with placebo surgery and 2) repair with physiotherapy. Institutional Review Board (IRB) of Tampere university hospital has approved the study protocol. All participants will give written informed consent. The results of the trial will be disseminated as published articles in peer-reviewed journals. Outcome measures for different studies are often derived from what clinicians, rather than patients, thinks to be important. The investigators chose to base the efficacy assessment on the measure of patient's subjective disability and pain. There is no clear evidence of the efficacy of the treatments (debridement and repair). It is justified and ethically correct to compare these treatments to placebo surgery and physiotherapy. Placebo surgery and physiotherapy are less invasive than debridement and repair and because of this are even safer to patients than comparable treatments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Triangular Fibrocartilage Complex Injury
Keywords
Arthroscopy, Surgery, Triangular Fibrocartilage, Randomized Controlled Trial, Placebo, Repair, Wrist

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
Lead investigators (LI), Coordinating research assistant (CRA), operating theatre staff and research assistants (RA) cannot be blinded to the allocation. Outcome assessors are blinded, and they do not participate in the care at any other point of the study than control visits. In the debridement versus placebo surgery randomization cohort all other hospital personnel and participant will be blinded. In repair of the TFCC (1B) versus physiotherapy randomization cohort we will not attempt blinding as the postoperative treatment is different; long immobilization of the physiotherapy group, and on the other hand, early mobilisation of the repair group may have negative impact on the outcomes.
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Central or Radial Tear: Arthroscopic debridement
Arm Type
Experimental
Arm Description
Arthroscopic debridement
Arm Title
Central or Radial Tear: Sham surgery
Arm Type
Placebo Comparator
Arm Description
Diagnostic arthroscopy only (placebo surgery).
Arm Title
Ulnar Tear: Arthroscopic or open repair
Arm Type
Experimental
Arm Description
Arthroscopic or open repair
Arm Title
Ulnar Tear: Physiotherapy
Arm Type
Active Comparator
Arm Description
Diagnostic arthroscopy and physiotherapy
Intervention Type
Procedure
Intervention Name(s)
Arthroscopic Debridement
Intervention Description
A central or radial TFCC tear found during wrist arthroscopy is debrided with a shaver. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation.
Intervention Type
Procedure
Intervention Name(s)
Placebo surgery
Intervention Description
Diagnostic arthroscopy only. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation. The procedure is placebo surgery.
Intervention Type
Procedure
Intervention Name(s)
Arthroscopic or Open Repair
Intervention Description
An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
Intervention Type
Procedure
Intervention Name(s)
Physiotherapy
Intervention Description
An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
Primary Outcome Measure Information:
Title
Patient-Rated Wrist Evaluation (PRWE)
Description
PRWE questionnaire is a validated wrist specific questionnaire consisting of 15-item questionnaire about pain and disability in daily living. PRWE gives a value between 0 (best) and 100 (worst). It is specific wrist instrument with good reliability, validity and responsiveness. In this trial we use minimal important difference (MID) value of 8. It is evaluated pre- and postoperatively.
Time Frame
10 year follow-up, primary time point at 1 year
Secondary Outcome Measure Information:
Title
EQ-5D-3L
Description
Health-related quality of life is measured pre- and postoperatively by EQ-5D-3L questionnaire. It is a generic instrument for assessing quality of life comprising five dimensions and VAS for health level. It is validated and widely used in healthcare research.
Time Frame
10 year follow-up
Title
Adverse and serious adverse events
Description
We will record all adverse events: tendon, ligament, nerve or arterial injury; fracture, CRPS, infection, chondral lesion and hematoma or any other condition, which can be attributed to the intervention. We will consider events leading to hospitalisation or death as serious adverse events and these will be recorded.
Time Frame
2 year follow-up
Title
Patient rated global improvement
Description
Global improvement is evaluated pre- and postoperatively by the question: "How would you rate the function and pain of your wrist compared to the situation before the treatment?" The options are in 7-step Likert scale from (-3) "Much worse" to (+3) "Much better". We will dichotomize the response between 0 (not better or worse) +1 (slightly better).
Time Frame
10 year follow-up
Title
Pain (VAS) in activity
Description
VAS in use is assessed pre- and postoperatively by VAS scale. The measurement of wrist pain in the affected hand is measured using a 100-mm horizontal line. Pain score is measured between 0 (mm, no pain) and 100 (mm, worst possible) pain. Higher score means worse outcome.
Time Frame
10 year follow-up
Title
Grip strength
Description
Grip strength is measured pre- and postoperatively with Jamar dynamometer using the handle in 2-position. Elbow is in 90° flexion and attached to chest. The result is reported in kilograms.
Time Frame
2 year follow-up
Title
Success of blinding with the patient and the outcome assessor
Description
At the two-year control it is asked from the patient and the outcome assessor which group they thought to belong treatment or placebo in central or radial tear randomization cohort. The success of blinding will be reported in per cents.
Time Frame
1 year follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ulnar sided wrist pain age more than 18 years suspicion of TFCC tear in clinical examination (MRI optional) ability to fill the Danish, Finnish, Norwegian or Swedish versions of questionnaires symptom duration more than 3 months, and unsuccessful conservative treatment central, radial or ulnar tear explaining the pain in arthroscopy Exclusion Criteria: unstable DRUJ which will be defined as "sign of complete instability in clinical examination" distal TFCC tear in arthroscopy ulnocarpal or DRUJ arthrosis ulnar variance ≥ +2 mm in x-rays age above 65 years rheumatoid arthritis or other inflammatory disease effecting radio- or ulnocarpal or DRUJ Lunotriquetral instability diagnosed in arthroscopy ECU instability massive tear and degenerated edges or frayed tear which fails suture
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ville M Mattila, M.D., Ph.D., Professor
Phone
+3583311611
Email
ville.mattila@tuni.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Jarkko Jokihaara, M.D., Ph.D., Professor
Phone
+3583311611
Email
jarkko.jokihaara@tuni.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antti Kaivorinne, M.D.
Organizational Affiliation
Tampere University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mikko P Räisänen, M.D.
Organizational Affiliation
Tampere University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Teemu Karjalainen, M.D., Ph.D.
Organizational Affiliation
Central Finland Central Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Aleksi Reito, M.D., Ph.D., Adjunct professor
Organizational Affiliation
Tampere University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Gvozdenovic, M.D.
Organizational Affiliation
Copenhagen University Hospital, Gentofte
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jan-Ragnar Haugstvedt, M.D., Ph.D.
Organizational Affiliation
Ostfold Hospital Trust
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maria Wilcke, M.D., Ph.D.
Organizational Affiliation
Karolinska University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Copenhagen University Hospital Gentofte
City
Copenhagen
ZIP/Postal Code
2900
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Gvozdenovic, M.D.
Phone
+45 38 67 38 67
Email
Robert.Gvozdenovic@regionh.dk
Facility Name
Central Finland Central Hospital
City
Jyväskylä
State/Province
Keski-Suomi
ZIP/Postal Code
40620
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Teemu Karjalainen, M.D., Ph.D.
Phone
+358142691811
Email
teemu.karjalainen@ksshp.fi
First Name & Middle Initial & Last Name & Degree
Toni Luokkala, M.D.
Phone
+358142691811
Email
toni.luokkala@ksshp.fi
Facility Name
Tampere University Hospital
City
Tampere
State/Province
Pirkanmaa
ZIP/Postal Code
33521
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antti Kaivorinne, M.D.
Phone
+3583311611
Email
antti.kaivorinne@pshp.fi
First Name & Middle Initial & Last Name & Degree
Margit C Karelson, M.D.
Phone
+3583311611
Email
margit.karelson@pshp.fi
Facility Name
Oulu University Hospital
City
Oulu
State/Province
Pohjois-Pohjanmaa
ZIP/Postal Code
90220
Country
Finland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johannes Kuorilehto, M.D.
Phone
+35883152011
Email
johannes.kuorilehto@psshp.fi
Facility Name
Kuopio University Hospital
City
Kuopio
State/Province
Pohjois-Savo
ZIP/Postal Code
70029
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matti Juntunen, M.D.
Phone
+35817173311
Email
matti.juntunen@kuh.fi
Facility Name
Helsinki University Hospital
City
Helsinki
State/Province
Uusimaa
ZIP/Postal Code
00029
Country
Finland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Panu Nordback, M.D.
Phone
+35894711
Email
panu.nordback@hus.fi
First Name & Middle Initial & Last Name & Degree
Jorma Ryhänen, M.D., Ph.D., Adjunct prof.
Phone
+35894711
Email
jorma.ryhanen@hus.fi
Facility Name
Turku University Hospital
City
Turku
State/Province
Varsinais-Suomi
ZIP/Postal Code
20521
Country
Finland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Markus Pääkkönen, M.D., Ph.D., Adjunct prof.
Phone
+35823130000
Email
markus.paakkonen@tyks.fi
First Name & Middle Initial & Last Name & Degree
Hanna-Stiina Taskinen, M.D., Ph.D.
Phone
+35823130000
Email
hannastiina.taskinen@tyks.fi
Facility Name
Østfold Hospital Trust
City
Grålum
ZIP/Postal Code
1714
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan-Ragnar Haugstvedt, M.D., Ph.D.
Phone
+47 69 86 00 00
Email
Jan-Ragnar.Haugstvedt@so-hf.no
Facility Name
Karolinska University Hospital
City
Stockholm
ZIP/Postal Code
171 76
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Wilcke, M.D., Ph.D.
Phone
+46 8 517 700 00
Email
maria.wilcke@sll.se

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All the IPD will be shared with other researchers by request.
IPD Sharing Time Frame
Data will be available after the publication and it will be available for 15 years.
IPD Sharing Access Criteria
By request.

Learn more about this trial

Trial Comparing Treatment Strategies in Triangular Fibrocartilage Complex Ruptures

We'll reach out to this number within 24 hrs